Crossmark

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

Crossref DOI link: https://doi.org/10.1038/bmt.2016.19

Published Online: 2016-02-22

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Burns, D M

Rana, S

Martin, E

Nagra, S

Ward, J

Osman, H

Bell, A I

Moss, P

Russell, N H

Craddock, C F

Fox, C P

Chaganti, S
License Information

Text and Data Mining valid from 2016-02-22
More Information

Article History

Received: 9 November 2015

Revised: 30 December 2015

Accepted: 4 January 2016

First Online: 22 February 2016

Competing interests

: SC and CPF have received travel grants and speaker honoraria from Roche UK.